Phosphodiesterase inhibitors: new opportunities for the treatment of asthma

Torphy, T J; Undem, B J
July 1991
Thorax;Jul1991, Vol. 46 Issue 7, p512
Academic Journal
No abstract available.


Related Articles

  • Atlanta Highlights Positive Roflumilast Trials.  // Chemical Market Reporter;10/6/2003, Vol. 264 Issue 11, p7 

    Reports on the positive results from the clinical tests of phosphodiesterase-4 inhibitor by Altana AG in Germany. Application for European regulatory approval; Treatment options for chronic obstructive pulmonary disease (COPD) and asthma; Competitiveness in the respiratory COPD sector.

  • New Advances and Potential Therapies for the Treatment of Asthma. Belvisi, Maria G.; Hele, David J.; Birrell, Mark A. // BioDrugs;2004, Vol. 18 Issue 4, p211 

    Asthma is a disease of the airways with an underlying inflammatory component. The prevalence and healthcare burden of asthma is still rising and is predicted to continue to rise in the current century. Inhaled β2-adrenoceptor agonists and corticosteroids form the basis of the treatments...

  • Phosphodiesterase as a novel target in Cancer Chemotherapy. Sandeep, G.; Bhasker, S.; Ranganath, Y. Sri // Internet Journal of Pharmacology;2009, Vol. 7 Issue 1, p1 

    The Phosphodiesterase inhibitors have been used for the treatment of non-malignant conditions like asthma, pulmonary hypertension and erectile dysfunction etc, but the recent research suggests that they have great therapeutic value in the adjunctive therapy of Cancer. This article reviews the...

  • Phosphodiesterases in the CNS: targets for drug development. Menniti, Frank S.; Faraci, W. Stephen; Schmidt, Christopher J. // Nature Reviews Drug Discovery;Aug2006, Vol. 5 Issue 8, p660 

    The therapeutic and commercial success of phosphodiesterase 5 inhibitors such as Viagra, Levitra and Cialis has sparked renewed interest in the phosphodiesterases as drug discovery targets. Virtually all the phosphodiesterases are expressed in the CNS, making this gene family a particularly...

  • New drugs for asthma. Barnes, Peter J. // Nature Reviews Drug Discovery;Oct2004, Vol. 3 Issue 10, p831 

    Asthma is a major and increasing global health problem and, despite major advances in therapy, many patients' symptoms are not adequately controlled. Treatment with combination inhalers, which contain a corticosteroid and long-actingß2 adrenoceptor agonist, is the most effective current...

  • Editorial [Guest Editor: Strategies for the Improvement of Asthma Therapy (Executive Editor: Andreas Pahl)]. Pahl, Andreas // Current Pharmaceutical Design;Sep2006, Vol. 12 Issue 25, p3173 

    Asthma bronchiale, affecting 155 millions people worldwide, has emerged as a major public health problem worldwide over the past 20 years. Although data indicate that current asthma therapies led to limited decreases in death rates, it continues to be a significant health care problem. As we...

  • NDA for 5-lipoxygenase inhibitor filed.  // Drug Topics;9/19/94, Vol. 138 Issue 18, p8 

    Reports on Abbott Laboratories' filing for a new drug application for zileuton, a 5-lipoxygenase inhibitor for the treatment of asthma.

  • Sildenafil Is Safe and Effective in Men with Stable CAD. Sadovsky, Richard // American Family Physician;9/1/2004, Vol. 70 Issue 5, p956 

    Comments on the use of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction. Incidence of death attributed to cardiovascular disease; Medication given to patients with coronary ischemia; Arrhythmogenic potential of all of the phosphodiesterase type 5 inhibitors.

  • Airway smooth muscle as a target of asthma therapy: history and new directions. Janssen, Luke J.; Killian, Kieran // Respiratory Research;2006, Vol. 7, p123 

    Ultimately, asthma is a disease characterized by constriction of airway smooth muscle (ASM). The earliest approach to the treatment of asthma comprised the use of xanthines and anti-cholinergics with the later introduction of anti-histamines and anti-leukotrienes. Agents directed at ion channels...

  • Cilostazol in intermittent claudication. Cariski, Alan T.; Lindmayer, Katalin // American Journal of Health-System Pharmacy;1/1/2002, Vol. 59 Issue 1, p81 

    Focuses on the use of the phosphodiesterase inhibitor cilostazol for the treatment of intermittent claudication. Mechanism of action; Drug effectivity; Superiority of cilostazol to pentoxifylline.


Read the Article


Sign out of this library

Other Topics